Management of hereditary antithrombin deficiency in pregnancy

Thromb Res. 2017 Sep:157:41-45. doi: 10.1016/j.thromres.2017.05.017. Epub 2017 May 24.

Abstract

Antithrombin (AT) deficiency is a high-risk thrombophilia and a rare condition. Despite full anticoagulation during pregnancy and the postpartum period, women with AT deficiency may still be vulnerable to developing venous thromboembolism (VTE), including fatal events. There is limited guidance on the management of AT deficiency in pregnancy, including the role of AT concentrates. Following a comprehensive review of the state of the art with respect to recommendations and guidelines, our expert panel in maternal-fetal medicine, hematology and basic science reached consensus on key issues in the recognition and management of AT deficiency in pregnancy. This paper summarizes the state of the art and summarizes what we believe are best practices with special emphasis on a multidisciplinary approach involving obstetrics and hematology in the care of women with AT deficiency.

MeSH terms

  • Antithrombin III Deficiency / drug therapy*
  • Antithrombin III Deficiency / pathology
  • Female
  • Humans
  • Postpartum Period
  • Pregnancy
  • Risk Factors